DOT1L and cancer: To further develop novel epigenetic regulators for intractable cancers, we revealed that PsA-3091, a tertiary butyl substituted heteromonomeric disulfide structured analog, showed DOT1L-dependent antitumor activity towards TNBC cells [18].